Stronvivo is an Informed Choice certified nutritional supplement comprised of natural, USP-verified, pharmaceutical-grade ingredients designed to improve the health of the endothelium, stimulate the production of nitric oxide, improve circulation, increase blood flow, boost energy and inhibit platelet aggregation and adherence, all of which play an integral role in both male and female sexual function.
Stronvivo is an effective treatment for female sexual dysfunction. stronvivo increases sexual desire, sexual arousal, orgasm satisfaction and lubrication.
Stronvivo Clinical Trial Results
Using the below-listed clinical tools, stronvivo demonstrated statistically significant improvements in both male and female sexual functioning.
For men, Stronvivo improved erectile functioning and increased sexual desire.
For women, Stronvivo increased sexual desire, increased sexual arousal, improved orgasms (frequency and pleasure), increased satisfaction, improved lubrication and reduced pain.
Stronvivo Clinical Tools and Scores
FSFI (Female Sexual Functioning Index), a 19-item questionnaire, has been developed as a brief, multidimensional self-report instrument for assessing the key dimensions of sexual function in women. It was developed on a female sample of normal controls and age-matched subjects who met DSM-IV®-TR criteria for female sexual arousal disorder (FSAD) and provides scores on six domains of sexual function (desire, arousal, lubrication, orgasm, satisfaction, and pain) as well as a total score. The FSFI has been validated on clinically diagnosed samples of women with female sexual arousal disorder (FSAD), female orgasmic disorder (FOD), and hypoactive sexual desire disorder (HSDD). See also FSFI Validation authored by Wiegel M, Meston C, Rosen R.
Stronvivo Clinical RESULTS
IIEF (International Index of Erectile Function) is designed to assess for treatment-related changes among patients with erectile dysfunction. The questionnaire contains 15 items that are rated on a 6-point Likert scale, which assess four domains of male sexual dysfunction: erectile function, orgasmic function, sexual desire, and intercourse satisfaction. See also IIEF Validation authored by Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A.
PHQ-9 (Patient Health Questionnaire) is widely used in primary care clinics, outpatient offices, and longitudinal research studies to monitor a patient’s symptoms of depression. This questionnaire is comprised of 9 items that correspond with the diagnostic criteria for depression included in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) . Each statement is rated on a 4-point, Likert scale.
PHQ-9 results exhibited statistically significant improvements in depressive symptoms occurred for males after 30 days and for females after 60 days. These improvements from baseline were maintained at the 60 and 90 day follow-up, respectively. Decreased scores indicate reduction in symptoms of depression.
ADAM (Androgen Deficiency in Aging Males) is designed to assess for symptoms of low testosterone.
ADAM - over half (51.2%) of the men meeting criteria for androgen deficiency at baseline no longer met criteria after 30 days of stronvivo supplementation. The percentage held constant at 60 days. After 90 days of stronvivo supplementation, 55.8% of the men meeting criteria for androgen deficiency at baseline no longer met criteria. The labeled/green areas indicate the percentage of men whose ADAM results indicated androgen deficiency at Baseline who subsequently indicated not likely to be androgen deficient after taking stronvivo for the time period noted on the x-axis.
(See published results: Journal of Sexual Medicine, International Society for the Study of Women's Sexual Health and here.)